Medical Case Reports

There were four fatalities among 65  fully vaccinated and boosted ( FV&B )  COVID-19 patients at an acute-care hospital system in Southeastern Michigan. In the FV&B cohort that required ICU-level care (n=11), 7 (63.6%) were male with a median age of 71 (66.5, 76.5). 5 (45.5%) were vaccinated with three consecutive Pfizer immunizations, 4 (36.4%) received three doses of the Moderna vaccine, and 2 (18.2%) received two Janssen vaccines. 4 (36.4%) died, 3 (27.2%) were discharged to a Skilled Nursing Facility (SNF), and 2 (18.2%) were discharged home. This data was collected b etween August 12th, 2021 and December 6th, 2021, for 4,571 patients with a primary diagnosis of COVID-19 who required inpatient treatment at an acute-care hospital system in Southeastern Michigan. Of the 4,571 encounters requiring hospitalization, 65(1.4%) were FV&B and 2,935(64%) were UV Despite older age (median 74 vs 58 years old), higher rate of pre-existing ESRD (18.5% vs 1.8%), higher ...

SUMMARY   We report a case from an ongoing COVID-19 vaccines long-term safety study . We describe a fatal SARS-CoV-2 breakthrough infection occurring after a serious adverse reaction to ChAdOx1 nCov-19 vaccine. Two years into the outbreak, COVID-19 treatment and preventive care are still not sufficiently personalized. Radiographic and laboratory findings commonly used to monitor progression to severe disease fail to select appropriate treatment or subsequent immunization regimen while predicting response to therapy remains a clinical challenge. Retrospectively analyzing post-immunization adverse events helps in understanding the relationship between host susceptibility and vaccine efficacy, which may ultimately lead to improved interventions. CASE PRESENTATION An otherwise healthy 84-year-old male tested positive for SARS-CoV-2 with a reverse transcription-polymerase chain reaction (RT-PCR) about 2 months af...